Regulus Therapeutics (NASDAQ:RGLS)

CAPS Rating: 1 out of 5

Results 1 - 3 of 3

Recs

0
Member Avatar usubanas (99.67) Submitted: 10/23/2014 1:22:41 PM : Underperform Start Price: $14.01 RGLS Score: -23.17

HCV results not that great to justify a 600M mc.

Recs

0
Member Avatar marsuculix (21.12) Submitted: 10/23/2014 7:36:35 AM : Underperform Start Price: $13.75 RGLS Score: -25.11

its HCV drug is still far away from being marketed...

Recs

0
Member Avatar rknapton (< 20) Submitted: 8/22/2013 4:56:09 PM : Underperform Start Price: $9.51 RGLS Score: -64.29

Short. Biotech. High P/S ratio.

Results 1 - 3 of 3

Featured Broker Partners


Advertisement